[go: up one dir, main page]

WO2025153015A3 - Conjugué d'inhibiteur de la traduction des protéines et son utilisation - Google Patents

Conjugué d'inhibiteur de la traduction des protéines et son utilisation

Info

Publication number
WO2025153015A3
WO2025153015A3 PCT/CN2025/072722 CN2025072722W WO2025153015A3 WO 2025153015 A3 WO2025153015 A3 WO 2025153015A3 CN 2025072722 W CN2025072722 W CN 2025072722W WO 2025153015 A3 WO2025153015 A3 WO 2025153015A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
protein translation
translation inhibitor
disease
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/072722
Other languages
English (en)
Chinese (zh)
Other versions
WO2025153015A2 (fr
Inventor
李冰
林圣超
张禹
花海清
朱忠远
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duality Biologics Suzhou Co Ltd
Original Assignee
Duality Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duality Biologics Suzhou Co Ltd filed Critical Duality Biologics Suzhou Co Ltd
Publication of WO2025153015A2 publication Critical patent/WO2025153015A2/fr
Publication of WO2025153015A3 publication Critical patent/WO2025153015A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un conjugué d'un inhibiteur de la traduction des protéines et son utilisation dans la préparation d'un médicament pour le traitement et/ou la prévention d'une maladie, ladite maladie étant une tumeur ou un cancer.
PCT/CN2025/072722 2024-01-16 2025-01-16 Conjugué d'inhibiteur de la traduction des protéines et son utilisation Pending WO2025153015A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202410063661.2 2024-01-16
CN202410063661 2024-01-16
CN202411574559 2024-11-06
CN202411574559.5 2024-11-06
CN202510025596.9 2025-01-07
CN202510025596 2025-01-07

Publications (2)

Publication Number Publication Date
WO2025153015A2 WO2025153015A2 (fr) 2025-07-24
WO2025153015A3 true WO2025153015A3 (fr) 2025-09-04

Family

ID=96470779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/072722 Pending WO2025153015A2 (fr) 2024-01-16 2025-01-16 Conjugué d'inhibiteur de la traduction des protéines et son utilisation

Country Status (1)

Country Link
WO (1) WO2025153015A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1989122A (zh) * 2004-05-18 2007-06-27 拜耳医药保健股份公司 新型环戊[b]苯并呋喃衍生物及其用途
WO2011140334A2 (fr) * 2010-05-06 2011-11-10 Trustees Of Boston University Composés, méthodes de fabrication ou d'identification de composés et leurs utilisations
CN102300568A (zh) * 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
CN109476648A (zh) * 2016-06-06 2019-03-15 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
WO2022140504A1 (fr) * 2020-12-23 2022-06-30 Shanghai Ruotuo Biosciences Co., Ltd. Conjugués anticorps-médicaments, compositions pharmaceutiques et applications thérapeutiques
CN115073407A (zh) * 2021-03-10 2022-09-20 上海中医药大学 一种具有合成致死性的药用组合物及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1989122A (zh) * 2004-05-18 2007-06-27 拜耳医药保健股份公司 新型环戊[b]苯并呋喃衍生物及其用途
CN102300568A (zh) * 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
WO2011140334A2 (fr) * 2010-05-06 2011-11-10 Trustees Of Boston University Composés, méthodes de fabrication ou d'identification de composés et leurs utilisations
CN109476648A (zh) * 2016-06-06 2019-03-15 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
WO2022140504A1 (fr) * 2020-12-23 2022-06-30 Shanghai Ruotuo Biosciences Co., Ltd. Conjugués anticorps-médicaments, compositions pharmaceutiques et applications thérapeutiques
CN115073407A (zh) * 2021-03-10 2022-09-20 上海中医药大学 一种具有合成致死性的药用组合物及其应用

Also Published As

Publication number Publication date
WO2025153015A2 (fr) 2025-07-24

Similar Documents

Publication Publication Date Title
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
CA2336624A1 (fr) Inhibiteurs de farnesyl proteine transferase a proprietes de radiosensibilisation in vivo
WO2000044364A3 (fr) INHIBITEURS DE p53 ET UTILISATION THERAPEUTIQUE DE CEUX-CI
DE69923322D1 (de) Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
WO1997029779A3 (fr) Conjugues de egf-genisteine pour le traitement du cancer
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
CA2373794A1 (fr) Compositions et utilisation d'et743 pour le traitement du cancer
WO2005048950A3 (fr) Compositions therapeutiques contre des maladies infectieuses et des tumeurs
WO2005054295A8 (fr) Anticorps therapeutiques et diagnostiques anti-hsp 70
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
EP2258702A3 (fr) Compositions purifiées de 10-Propargyl-10-Deazaaminopterine et procédés d'utilisation de ces dernières dans le traitement de tumeurs
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
WO2025153015A3 (fr) Conjugué d'inhibiteur de la traduction des protéines et son utilisation
CA2363973A1 (fr) Amelioration de l'efficacite du 5-fluorouracil dans le traitement des metastases et du cancer
WO2001041747A3 (fr) Preparation pharmaceutique pour traiter des affections tumorales
WO2000006136A3 (fr) METHODE PERMETTANT DE TRAITER LE CANCER CHEZ DES PATIENTS PRESENTANT UNE DEFICIENCE DU SUPPRESSEUR DE TUMEUR p53
IL158058A (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
EP0919244A3 (fr) Combinaisons pour le traitement des tumeurs
RU2004101182A (ru) Способ предоперационного лечения рака молочной железы
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2000035469A3 (fr) Therapie a base de gonadotrophine chorionique destinee au traitement du cancer du sein
WO1997033620A3 (fr) Compose pour traiter des tumeurs
IL159770A0 (en) Calcium salts with cytotoxic activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25741576

Country of ref document: EP

Kind code of ref document: A2